These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27387643)

  • 1. Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration.
    Zetterberg H
    Neuron; 2016 Jul; 91(1):1-3. PubMed ID: 27387643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The third wave: Intermediate filaments in the maturing nervous system.
    Kirkcaldie MTK; Dwyer ST
    Mol Cell Neurosci; 2017 Oct; 84():68-76. PubMed ID: 28554564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of the neuronal intermediate filaments.
    Okabe S; Miyasaka H; Hirokawa N
    J Cell Biol; 1993 Apr; 121(2):375-86. PubMed ID: 8468352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New movements in neurofilament transport, turnover and disease.
    Barry DM; Millecamps S; Julien JP; Garcia ML
    Exp Cell Res; 2007 Jun; 313(10):2110-20. PubMed ID: 17451679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary.
    Hutchinson M
    Mult Scler; 2015 Sep; 21(10):1242-3. PubMed ID: 26242693
    [No Abstract]   [Full Text] [Related]  

  • 6. Spontaneous perikaryal neurofilament phosphorylation in the septofimbrial nucleus of the rat.
    Klosen P; van den Bosch de Aguilar P
    Neurosci Lett; 1992 May; 139(1):108-13. PubMed ID: 1407676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament protein phosphorylation: topographic regulation and functions.
    Pant HC; Floyd CC; Dosemeci A
    Adv Second Messenger Phosphoprotein Res; 1990; 24():393-8. PubMed ID: 2119648
    [No Abstract]   [Full Text] [Related]  

  • 8. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.
    Bacioglu M; Maia LF; Preische O; Schelle J; Apel A; Kaeser SA; Schweighauser M; Eninger T; Lambert M; Pilotto A; Shimshek DR; Neumann U; Kahle PJ; Staufenbiel M; Neumann M; Maetzler W; Kuhle J; Jucker M
    Neuron; 2016 Jul; 91(1):56-66. PubMed ID: 27292537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament Biophysics: From Structure to Biomechanics.
    Ding EA; Kumar S
    Mol Biol Cell; 2024 May; 35(5):re1. PubMed ID: 38598299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The amount of neurofilaments aggregated in the cell body is controlled by their increased sensitivity to trypsin-like proteases.
    Fasani F; Bocquet A; Robert P; Peterson A; Eyer J
    J Cell Sci; 2004 Feb; 117(Pt 6):861-9. PubMed ID: 14762113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
    Petzold A
    J Neurol Sci; 2005 Jun; 233(1-2):183-98. PubMed ID: 15896809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment resistance in major depression is correlated with increased plasma levels of neurofilament light protein reflecting axonal damage.
    Spanier S; Kilian HM; Meyer DM; Schlaepfer TE
    Med Hypotheses; 2019 Jun; 127():159-161. PubMed ID: 31088642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neurofilament light chain level as a biomarker of neurodegeneration and predictor of white-matter abnormality progression.
    Murthy JK; Das S
    Eur J Neurol; 2020 Oct; 27(10):e55. PubMed ID: 32526090
    [No Abstract]   [Full Text] [Related]  

  • 14. Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration.
    Miller AM; Rutkowska A; Bahl JM; Herukka SK; Koel-Simmelink MJ; Kruse N; Mollenhauer B; Siloaho M; Skinningsrud A; Zetterberg H; Teunissen CE; Lawlor BA
    Bioanalysis; 2016 Nov; 8(21):2243-2254. PubMed ID: 27684648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cdk5 regulates axonal transport and phosphorylation of neurofilaments in cultured neurons.
    Shea TB; Yabe JT; Ortiz D; Pimenta A; Loomis P; Goldman RD; Amin N; Pant HC
    J Cell Sci; 2004 Feb; 117(Pt 6):933-41. PubMed ID: 14762105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges.
    Coppens S; Lehmann S; Hopley C; Hirtz C
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO.
    Arrambide G; Espejo C; Tintore M
    Mult Scler; 2015 Sep; 21(10):1240-2. PubMed ID: 26242692
    [No Abstract]   [Full Text] [Related]  

  • 18. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level - YES.
    Salzer J
    Mult Scler; 2015 Sep; 21(10):1239-40. PubMed ID: 25828757
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-neurofilament antibodies and neurodegeneration: Markers and generators.
    Zmira O; Halpern AI; Drori T
    J Neuroimmunol; 2020 Jul; 344():577248. PubMed ID: 32344161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament light polypeptide gene N98S mutation in mice leads to neurofilament network abnormalities and a Charcot-Marie-Tooth Type 2E phenotype.
    Adebola AA; Di Castri T; He CZ; Salvatierra LA; Zhao J; Brown K; Lin CS; Worman HJ; Liem RK
    Hum Mol Genet; 2015 Apr; 24(8):2163-74. PubMed ID: 25552649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.